NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $15.67.
A number of research analysts recently weighed in on the stock. Lake Street Capital restated a “buy” rating and set a $12.00 target price on shares of NeuroPace in a research note on Wednesday, December 27th. SVB Leerink began coverage on shares of NeuroPace in a report on Tuesday, January 30th. They issued an “outperform” rating and a $22.00 target price for the company. Cantor Fitzgerald upped their target price on shares of NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Leerink Partnrs reaffirmed an “outperform” rating on shares of NeuroPace in a report on Tuesday, January 30th. Finally, Wells Fargo & Company raised shares of NeuroPace from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $16.00 to $20.00 in a report on Thursday, March 14th.
Get Our Latest Research Report on NPCE
Insider Buying and Selling at NeuroPace
Institutional Trading of NeuroPace
Several hedge funds have recently made changes to their positions in NPCE. Citigroup Inc. purchased a new stake in shares of NeuroPace during the 3rd quarter valued at about $29,000. Renaissance Technologies LLC purchased a new stake in shares of NeuroPace during the 2nd quarter valued at about $63,000. Susquehanna International Group LLP purchased a new stake in shares of NeuroPace during the 1st quarter valued at about $65,000. Barclays PLC raised its position in NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock worth $105,000 after purchasing an additional 10,721 shares during the period. Finally, Geode Capital Management LLC raised its position in NeuroPace by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 71,515 shares of the company’s stock worth $106,000 after purchasing an additional 5,945 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
NeuroPace Stock Up 1.8 %
NASDAQ NPCE opened at $14.00 on Friday. NeuroPace has a 52 week low of $3.80 and a 52 week high of $18.15. The company has a quick ratio of 5.02, a current ratio of 5.71 and a debt-to-equity ratio of 2.76. The company has a market capitalization of $367.92 million, a P/E ratio of -10.94 and a beta of 2.08. The stock’s 50-day moving average price is $14.53 and its 200-day moving average price is $11.36.
NeuroPace (NASDAQ:NPCE – Get Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.10. NeuroPace had a negative net margin of 50.38% and a negative return on equity of 153.76%. The company had revenue of $18.01 million during the quarter, compared to analyst estimates of $17.74 million. On average, equities research analysts predict that NeuroPace will post -1.14 earnings per share for the current year.
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Read More
- Five stocks we like better than NeuroPace
- Using the MarketBeat Dividend Yield Calculator
- Comprehensive PepsiCo Stock Analysis
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.